www.genesistherapeutics.ai Open in urlscan Pro
188.114.96.3  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Genesis Therapeutics Closes Oversubscribed $200M Series BRead more ->
Home Company Platform Press Careers Contact Us


Company
Platform
Press
Careers
Contact Us


AI-POWERED
DRUG DISCOVERY

Unlocking novel protein targets, exploring untapped chemical space, and
accelerating the development of critical new medicines with the industry's most
advanced molecular AI platform.

Our Company
Our Platform ->

Our Company
We’re a tight-knit team of proven drug hunters, deep learning researchers, and
software engineers collaborating to drive AI in biochemistry, discovering and
developing new therapies for patients suffering from severe disorders.

Learn more ->


Our Platform
A pioneering approach to AI for biotech:
3D spatial graph modeling + cutting-edge molecular simulation to generate novel
drug candidates.

Learn more ->

Investors

In the press
Andreessen Co-Leads $200 Million Investment in Biotech Startup Genesis
Therapeutics

Genesis Therapeutics announces AI discovery deal with Eli Lilly, $20M in upfront
cash with potential total value of $670M

Genesis Therapeutics Hires Will McCarthy as Chief Business Officer

Genesis Therapeutics raises $52M A round for its AI-focused drug discovery
mission

Roche's James Sabry partners Genentech with Stanford spin­out Genesis
Therapeutics
Company
Platform
Press
Careers
Contact Us
© 2022 Genesis Therapeutics Inc.
BD Inquiries: bd@genesistherapeutics.ai

General Info: info@genesistherapeutics.ai